tiprankstipranks
Shanghai Pharmaceuticals Holding Co Ltd Class H (HK:2607)
:2607
Hong Kong Market
2607
Shanghai Pharmaceuticals Holding Co
RESEARCH TOOLSreports

Shanghai Pharmaceuticals Holding Co (2607) Income Statement

5 Followers

Shanghai Pharmaceuticals Holding Co Income Statement

Last quarter (Q4 2025), Shanghai Pharmaceuticals Holding Co's total revenue was ¥68.51B, an increase of 4.40% from the same quarter last year. In Q4, Shanghai Pharmaceuticals Holding Co's net income was ¥577.49M. See Shanghai Pharmaceuticals Holding Co’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
¥ 283.58B¥ 275.25B¥ 260.30B¥ 231.98B¥ 215.82B
Gross Profit
¥ 30.42B¥ 30.63B¥ 30.93B¥ 30.49B¥ 28.54B
Operating Expenses
¥ 20.47B¥ 22.49B¥ 23.26B¥ 21.71B¥ 20.62B
Depreciation and Amortization
¥ 2.86B¥ 2.42B¥ 2.19B¥ 2.22B¥ 2.14B
EBITDA
¥ 14.37B¥ 12.06B¥ 10.90B¥ 12.44B¥ 10.55B
Operating Income
¥ 9.94B¥ 8.14B¥ 7.67B¥ 9.01B¥ 8.21B
Other Income/Expenses
¥ -122.28M¥ -120.71M¥ -612.94M¥ -206.30M¥ -61.67M
Pretax Income
¥ 9.82B¥ 8.02B¥ 7.05B¥ 8.81B¥ 8.14B
Net Income
¥ 5.72B¥ 4.55B¥ 3.77B¥ 5.62B¥ 5.09B
Per Share Metrics
Basic EPS
¥ 1.54¥ 1.23¥ 1.02¥ 1.61¥ 1.79
Diluted EPS
¥ 1.54¥ 1.23¥ 1.02¥ 1.61¥ 1.79
Weighted Average Shares Outstanding
 3.71B 3.70B 3.70B 3.48B 2.84B
Weighted Average Shares Outstanding (Diluted)
 3.71B 3.70B 3.70B 3.49B 2.85B
Currency in CNY

Shanghai Pharmaceuticals Holding Co Earnings and Revenue History